" class="no-js "lang="en-US"> ObvioHealth Expands Digital Health Research Ecosystem Through New Global Licensing Agreement With Dedalus - Medtech Alert
Tuesday, January 21, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ObvioHealth Expands Digital Health Research Ecosystem Through New Global Licensing Agreement With Dedalus | Pharmtech Focus

June 28 2022

ObvioHealth Expands Digital Health Research Ecosystem Through New Global Licensing Agreement With Dedalus

ObvioHealth, a global virtual research organization (VRO), extends its strategic alliance with Dedalus Group (“Dedalus”), the leading healthcare and diagnostic software solutions provider in Europe, to include global licensing of Dedalus’s technology.
The two companies first partnered in 2021 to allow ObvioHealth to evaluate anonymized analytics of Dedalus’s healthcare records. This new agreement grants ObvioHealth use of Dedalus’s data mining and analytics tools for their own research as well as that of its partners and sponsors. This technology will enable access to analytics of ObvioHealth’s own multi-source healthcare data to inform better clinical trial design and recruitment as well as longitudinal disease and treatment trends.
Partner sites and their providers will also be able to propose clinical trials to their patients, a key area of opportunity given a recent WRG Market Analysis indicating that only 3% of physicians and 5% of patients currently participate in clinical trials. The data will also help train AI-enabled digital and diagnostic instruments to provide deeper analysis of certain disease states.
“We are pleased to provide ObvioHealth with a platform that can harmonize a seamless flow of multi-source data from disparate healthcare applications into a standard compliant and secure ecosystem,” said Koenraad Batselier, Vice President for Life Sciences at Dedalus Group. “By linking data sets semantically and normalizing them to an industry standard, we are opening up a whole new market—providing data infrastructure for clinical research in a way that was not previously possible.”
ObvioHealth’s digital research ecosystem includes digital devices and instruments, used primarily for the purpose of conducting decentralized clinical trials. This agreement with Dedalus will strengthen ObvioHealth’s capabilities in the identification and analysis of disease, comorbidity and treatment patterns that can assist providers with decisions in a real clinical workflow.
“The power of this ecosystem goes beyond clinical trials,” said Ivan Jarry, CEO of ObvioHealth. “With the ability to aggregate complex data sets we unlock a wealth of possibilities —from identifying disease correlations and trends to uncovering new indications for treatment.”

People In This Post

Koenraad Batselier

Koenraad Batselier
Ivan Jarry

Ivan Jarry

Companies In This Post

Dedalus Group | Pharmtech Focus

Dedalus Group
ObvioHealth | Pharmtech Focus

ObvioHealth
  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On